We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00713960
First Posted: July 14, 2008
Last Update Posted: January 16, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

Condition
Cardiovascular Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: CARE - Quality Development in Cardiovascular Disease in General Practice

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken [ Time Frame: As needed, min. baseline and after 6 months ]

Secondary Outcome Measures:
  • Number of visits pr. patients, drop-out [ Time Frame: Annually ]

Enrollment: 2193
Study Start Date: April 2008
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients in secondary prevention of cardiovascular disease in primary care

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic
Criteria

Inclusion Criteria:

  • Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

  • Patients who suffer from diabetic nephropathy will be excluded
  • According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00713960


  Show 66 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Chair: Henrik Ommen, MD Lægerne i Løgumkloster I/S, Denmark
Study Chair: Dorte Knudsen Lægerne Sønderåparken, Denmark
  More Information

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00713960     History of Changes
Other Study ID Numbers: NIS-CDK-DUM-2008/1
First Submitted: July 10, 2008
First Posted: July 14, 2008
Last Update Posted: January 16, 2012
Last Verified: January 2012

Keywords provided by AstraZeneca:
Quality development project
primary care nurses
cardiovascular disease
secondary prevention
follow-up

Additional relevant MeSH terms:
Cardiovascular Diseases